Industry Appeals India Caps On Key Drug Prices
This article was originally published in PharmAsia News
Executive Summary
Drug companies that market in India have appealed to the government to review the decision of its National Pharmaceutical Pricing Authority regarding price caps. Ranbaxy Laboratories and foreign pharmas object to the NPPA's caps on antibiotics, painkillers and erectile dysfunction drugs, as well as other big-selling brand treatments. But before the government agrees to review the caps, it asked some of the protesting firms to comply first, at least with regard to 10 key brands. Only then would the Chemicals and Fertilisers Ministry consider the company complaints. (Click here for more